| Literature DB >> 31604961 |
Reda Rawi1, Raghvendra Mall2, Chen-Hsiang Shen1, S Katie Farney1, Andrea Shiakolas1, Jing Zhou1, Halima Bensmail2, Tae-Wook Chun3, Nicole A Doria-Rose1, Rebecca M Lynch4, John R Mascola1, Peter D Kwong1, Gwo-Yu Chuang5.
Abstract
Broadly neutralizing antibodies (bNAbs) targeting the HIV-1 envelope glycoprotein (Env) have promising utility in prevention and treatment of HIV-1 infection, and several are currently undergoing clinical trials. Due to the high sequence diversity and mutation rate of HIV-1, viral isolates are often resistant to specific bNAbs. Currently, resistant isolates are commonly identified by time-consuming and expensive in vitro neutralization assays. Here, we report machine learning classifiers that accurately predict resistance of HIV-1 isolates to 33 bNAbs. Notably, our classifiers achieved an overall prediction accuracy of 96% for 212 clinical isolates from patients enrolled in four different clinical trials. Moreover, use of gradient boosting machine - a tree-based machine learning method - enabled us to identify critical features, which had high accordance with epitope residues that distinguished between antibody resistance and sensitivity. The availability of an in silico antibody resistance predictor should facilitate informed decisions of antibody usage and sequence-based monitoring of viral escape in clinical settings.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31604961 PMCID: PMC6789020 DOI: 10.1038/s41598-019-50635-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Potential clinical applications of bNAb-ReP. (A) bNAb-ReP can be applied during pre-screening of future patients for their neutralization susceptibility to bNAb used for treatment. (B) bNAb-ReP can be applied during treatment phase to monitor if viral escape to the used bNAb has occurred.
Figure 2bNAb-ReP development flowchart.
Figure 3bNAb-ReP prediction performance. Prediction performance (AUC) of 33 bNAb classifiers determined by ten runs of ten-fold cross-validation, color-coded based on epitope category.
Figure 4Top three discriminative features for VRC01 and 8ANC195 classifier. (A) The top three discriminant features of the bNAb VRC01 classifier are listed in the table and highlighted on the prefusion-closed Env trimer structure in complex with VRC01 antibody (PDB ID: 5FYJ). (B) The top three discriminant features of the bNAb 8ANC195 classifier are listed in the table and highlighted in the Env trimer structure in complex with 8ANC195 bNAb, with glycans 234 and 276 depicted as green sticks (PDB ID: 5CJX).
Features with variable importance of greater than 5% for 21 bNAb-ReP predictors.
| bNAb | Features with variable importance of greater than 5% |
|---|---|
| 10–1074 | |
| 2F5 | |
| 2G12 | |
| 3BNC117 | |
| 4E10 | 787B_L, |
| 8ANC195 | |
| b12 | 185_D |
| HJ16 |
|
| NIH45–46 | 364_S, |
| PG16 |
|
| PG9 | |
| PGT128 | 334_S, |
| PGT135 | 334_S, |
| PGT145 | |
| PGT151 | 651_N, 602_L, |
| VRC-CH31 | |
| VRC-PG04 | |
| VRC01 | |
| VRC13 | |
| VRC34.01 |
|
| VRC38.01 |
Features that were associated with epitope residues are highlighted in bold. @ denotes N-linked glycan sequon.
Figure 5bNAb-ReP prediction performance on VRC601 clinical HIV-1 isolates. (A) Prediction performance of the susceptibility of VRC601 clinical isolates to VRC01. In vitro assay neutralization classification is shown on the x-axis, with the in silico predicted probability for a sequence to be sensitive to VRC01 shown on the y-axis. The classification cutoff of 0.5 is depicted with a grey dashed line. (B) Bar plots depicting the number of in vitro classified VRC601 HIV-1 isolates per patient. Clinical HIV-1 isolates in silico predictions are shown in red (resistant) and cyan (sensitive) with darker colors indicating true predictions and light colors indicating false predictions.
Figure 6bNAb-ReP prediction performance on clinical HIV-1 isolates from Bar et al. and Ssemwanga et al. studies. (A) Bar plots highlighting the number of clinical HIV-1 isolates, introduced in the Bar et al. study, separated according to their in silico predictions. Resistant in silico predictions for bNAbs VRC01, 3BNC117, 10–1074, and PGT121 are shown in red and sensitive in cyan, with darker colors representing accurate predictions and light colors inaccurate ones, respectively. (B) Bar plots depicting the number of isolates, introduced by Ssemwanga et al., with resistant in silico predictions shown in red and sensitive in cyan.